Market Cap : 440.57 B | Enterprise Value : 436.71 B | PE Ratio : 24.38 | PB Ratio : 5.78 |
---|
NYSE:JNJ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:JNJ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Johnson & Johnson's annualized ROCE % for the quarter that ended in Jun. 2022 was 17.55%.
The historical data trend for Johnson & Johnson's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson & Johnson's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2021 ) | (A: Dec. 2020 ) | (A: Dec. 2021 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2021 ) | (A: Dec. 2020 ) | (A: Dec. 2021 ) | |||||
= | 22959 | / | ( ( (174894 - 42493) | + | (182018 - 45226) ) | / 2 ) | |
= | 22959 | / | ( (132401 | + | 136792) | / 2 ) | |
= | 22959 | / | 134596.5 | ||||
= | 17.06 % |
Johnson & Johnson's ROCE % of for the quarter that ended in Jun. 2022 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Jun. 2022 ) | (Q: Mar. 2022 ) | (Q: Jun. 2022 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Jun. 2022 ) | (Q: Mar. 2022 ) | (Q: Jun. 2022 ) | |||||
= | 23512 | / | ( ( (178355 - 43390) | + | (177724 - 44821) ) | / 2 ) | |
= | 23512 | / | ( ( 134965 | + | 132903 ) | / 2 ) | |
= | 23512 | / | 133934 | ||||
= | 17.55 % |
(1) Note: The EBIT data used here is four times the quarterly (Jun. 2022) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Johnson & Johnson's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Adamczyk Darius | director | 855 S. MINT STREET CHARLOTTE NC 28202 |
Hait William | officer: See Remarks | ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Mammen Mathai | officer: EVP, Pharm, R&D | THERAVANCE,INC. 901 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 |
Broadhurst Vanessa | officer: EVP, Global Corp Aff. | ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Swanson James D. | officer: EVP, Chief Information Officer | ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
West Nadja | director | 1915 REXFORD ROAD CHARLOTTE NC 28211 |
Decker Robert J | officer: Controller, CAO | ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Joly Hubert | director | C/O BEST BUY CO, INC. 7601 PENN AVENUE SOUTH RICHFIELD MN 55423 |
Weinberger Mark A | director | METLIFE, INC. 200 PARK AVENUE NEW YORK NY 10166 |
Hewson Marillyn A | director | C/O CARPENTER TECHNOLOGY CORPORATION PO BOX 14662 READING PA 19612-4662 |
Mongon Thibaut | officer: Exec VP, WW Chair, Consumer | JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Wengel Kathryn E | officer: EVP, Chief GSC Officer | JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Wolk Joseph J | officer: Exec VP, CFO | JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Mcevoy Ashley | officer: EVP, WW Chair, Medical Devices | JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Taubert Jennifer L | officer: EVP, WW Chair, Pharmaceuticals | JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
From GuruFocus
Other Sources
By Fool 2022-03-25
By Zacks 2022-03-24
By Zacks 2022-03-28
By Zacks 2022-03-22
By tipranks.com 2022-04-01
By Zacks 2022-03-30
By Zacks 2022-03-14
By Zacks 2022-03-21
By Zacks 2022-03-15
By Zacks 2022-03-18
By Zacks 2022-03-21
By Fool 2022-03-31
By Zacks 2022-03-24
By Zacks 2022-03-16